AR114965A2 - Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina - Google Patents

Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina

Info

Publication number
AR114965A2
AR114965A2 ARP190101607A ARP190101607A AR114965A2 AR 114965 A2 AR114965 A2 AR 114965A2 AR P190101607 A ARP190101607 A AR P190101607A AR P190101607 A ARP190101607 A AR P190101607A AR 114965 A2 AR114965 A2 AR 114965A2
Authority
AR
Argentina
Prior art keywords
phenyl
hydrochloride salt
trifluorophenoximethyl
piperidine hydrochloride
piperidine
Prior art date
Application number
ARP190101607A
Other languages
English (en)
Inventor
Lori Jean Patterson
Robert S Chao
Miroslav Rapta
Original Assignee
Theravance Biopharma R&D Ip Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR114965(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Biopharma R&D Ip Llc filed Critical Theravance Biopharma R&D Ip Llc
Publication of AR114965A2 publication Critical patent/AR114965A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)

Abstract

Reivindicación 1: Una sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]-piperidina caracterizada porque presenta un patrón de difracción de rayos X en polvo que comprende picos de difracción en valores 2q de 4,44 ± 0,20, 10,22 ± 0,20, 16,06 ± 0,20 y 21,78 ± 0,20.
ARP190101607A 2008-11-14 2019-06-11 Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina AR114965A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14

Publications (1)

Publication Number Publication Date
AR114965A2 true AR114965A2 (es) 2020-11-11

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP090104418A AR074350A1 (es) 2008-11-14 2009-11-13 Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
ARP090104419A AR074128A1 (es) 2008-11-14 2009-11-13 Derivados de 4-[2-(2-fluorofenoximetil)fenil] piperidina, composiciones farmaceuticas que los contienen, metodo de preparacion, compuestos intermediarios de dicho proceso y uso de los mismos para el tratamiento de dolores neuropaticos, mal de alzheimer y otras enfermedades relacionadas con el snc.
ARP190101607A AR114965A2 (es) 2008-11-14 2019-06-11 Sal de clorhidrato cristalina de 4-[2-(2,4,6-trifluorofenoximetil)fenil]piperidina

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP090104418A AR074350A1 (es) 2008-11-14 2009-11-13 Forma cristalina de un compuesto de 4-(2-(2- fluorofenoximetil) fenil ) pipiridina
ARP090104419A AR074128A1 (es) 2008-11-14 2009-11-13 Derivados de 4-[2-(2-fluorofenoximetil)fenil] piperidina, composiciones farmaceuticas que los contienen, metodo de preparacion, compuestos intermediarios de dicho proceso y uso de los mismos para el tratamiento de dolores neuropaticos, mal de alzheimer y otras enfermedades relacionadas con el snc.

Country Status (28)

Country Link
US (23) US8247433B2 (es)
EP (3) EP2358674B1 (es)
JP (6) JP5506813B2 (es)
KR (3) KR101656339B1 (es)
CN (3) CN102216271B (es)
AR (3) AR074350A1 (es)
AU (3) AU2009313951B2 (es)
BR (3) BRPI0921596B1 (es)
CA (3) CA2742105C (es)
CL (2) CL2011001088A1 (es)
CO (2) CO6361988A2 (es)
CY (3) CY1113622T1 (es)
DK (3) DK2358674T3 (es)
ES (3) ES2401224T3 (es)
HR (3) HRP20120920T1 (es)
IL (2) IL212230A (es)
MX (3) MX2011005089A (es)
MY (2) MY151229A (es)
NZ (2) NZ592413A (es)
PL (3) PL2358675T3 (es)
PT (3) PT2358675E (es)
RU (2) RU2515612C2 (es)
SG (1) SG171311A1 (es)
SI (3) SI2358675T1 (es)
SM (3) SMT201200063B (es)
TW (3) TWI443087B (es)
WO (3) WO2010056941A1 (es)
ZA (1) ZA201103495B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2358675T1 (sl) 2008-11-14 2013-01-31 Theravance, Inc. 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
WO2011085291A1 (en) * 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
EP2560646B1 (en) 2010-04-22 2014-12-17 Theravance Biopharma R&D IP, LLC Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
CN103547580B (zh) 2011-03-22 2016-12-07 阿迪维纳斯疗法有限公司 取代的稠合三环化合物、其组合物及医药用途
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
PL3506900T3 (pl) * 2016-08-30 2025-02-17 Theravance Biopharma R&D Ip, Llc Ampreloksetyna do zastosowania w leczeniu neurogennej hipotensji ortostatycznej
JP7252978B2 (ja) 2018-06-01 2023-04-05 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ２－（１－（ｔｅｒｔ－ブトキシカルボニル）ピペリジン－４－イル）安息香酸を調製するためのプロセス
JP2025509836A (ja) 2022-03-28 2025-04-11 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 多系統萎縮症の処置に使用するためのアンプレロキセチン
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) * 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) * 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) * 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
CN1309638A (zh) * 1998-07-10 2001-08-22 阿斯特拉曾尼卡有限公司 作为神经激肽受体拮抗剂的n－取代的萘甲酰胺
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6518284B2 (en) 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
EP1162196A4 (en) * 1999-12-27 2003-04-16 Japan Tobacco Inc COMPOUNDS WITH JOINED CYCLES AND THEIR USE AS MEDICAMENTS
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) * 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
DE60324685D1 (de) 2002-08-23 2008-12-24 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin-wiederaufnahme-inhibitoren
HRP20080262T3 (hr) * 2003-04-04 2009-04-30 H. Lundbeck A/S Derivati 4-(2-feniloksifenil)-piperidin ili -1,2,3,6 tetrahidropiridin kao inhibitori ponovne apsorpcije serotonina
EA009417B1 (ru) * 2003-04-04 2007-12-28 Х. Лундбекк А/С Производные 4-(2-фенилоксифенил)пиперидина или -1,2,3,6-тетрагидропиридина в качестве ингибиторов обратного захвата серотонина
ES2305776T3 (es) 2003-06-17 2008-11-01 Pfizer Inc. Derivados de n-pirrolidin-3-il-amida como inhibidores de la re-captacion de serotonina y noradrenalina.
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
CA2553289A1 (en) 2004-01-13 2005-07-28 Pfizer Inc. Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-uptake inhibitors
WO2005092835A1 (en) * 2004-03-05 2005-10-06 Eli Lilly And Company Pharmaceutical compounds
AU2005238296A1 (en) 2004-04-30 2005-11-10 Warner-Lambert Company Llc Substituted morpholine compounds for the treatment of central nervous system disorders
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
CA2661187A1 (en) 2006-08-23 2008-02-28 Pfizer Products Inc. Piperidine derivatives
EP2068867A2 (en) * 2006-09-27 2009-06-17 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
CN102203074A (zh) 2008-06-20 2011-09-28 麦它波莱克斯股份有限公司 芳基gpr119激动剂及其用途
JP5405571B2 (ja) 2008-07-24 2014-02-05 セラヴァンス， インコーポレーテッド ３−（フェノキシフェニルメチル）ピロリジン化合物
SI2358675T1 (sl) 2008-11-14 2013-01-31 Theravance, Inc. 4-(2-(2-fluorofenoksimetil)fenil)piperidinske spojine
WO2011085291A1 (en) 2010-01-11 2011-07-14 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
EP2550252B1 (en) 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
PL3506900T3 (pl) * 2016-08-30 2025-02-17 Theravance Biopharma R&D Ip, Llc Ampreloksetyna do zastosowania w leczeniu neurogennej hipotensji ortostatycznej

Also Published As

Publication number Publication date
NZ592413A (en) 2013-02-22
US8802857B2 (en) 2014-08-12
PL2358675T3 (pl) 2013-03-29
JP2014101384A (ja) 2014-06-05
US8592596B2 (en) 2013-11-26
BRPI0921596A2 (pt) 2018-03-20
AU2009313951A1 (en) 2010-05-20
BRPI0921595B8 (pt) 2021-05-25
PT2358674E (pt) 2013-03-05
US20100125092A1 (en) 2010-05-20
CN102216272B (zh) 2014-02-05
US20130030020A1 (en) 2013-01-31
US9675599B2 (en) 2017-06-13
US20180050024A1 (en) 2018-02-22
CN102216272A (zh) 2011-10-12
CA2739992A1 (en) 2010-05-20
IL212230A0 (en) 2011-06-30
SI2358674T1 (sl) 2013-04-30
AU2009313948B2 (en) 2015-03-12
US20190142816A1 (en) 2019-05-16
US20200316048A1 (en) 2020-10-08
US20190134019A1 (en) 2019-05-09
JP2012508759A (ja) 2012-04-12
US10441579B2 (en) 2019-10-15
US9073859B2 (en) 2015-07-07
CN102216271B (zh) 2013-09-25
HK1160452A1 (en) 2012-08-17
BRPI0921593B1 (pt) 2021-05-04
AU2009313949A1 (en) 2010-05-20
US10226454B2 (en) 2019-03-12
HRP20130300T1 (hr) 2013-04-30
HK1160448A1 (en) 2012-08-17
CY1113855T1 (el) 2016-07-27
US10946007B2 (en) 2021-03-16
US8304432B2 (en) 2012-11-06
PT2358675E (pt) 2012-12-12
US8604058B2 (en) 2013-12-10
WO2010056939A1 (en) 2010-05-20
SMT201200063B (it) 2013-01-14
US20230201181A1 (en) 2023-06-29
MY151229A (en) 2014-04-30
TW201022206A (en) 2010-06-16
CL2011001088A1 (es) 2011-10-14
CO6361988A2 (es) 2012-01-20
BRPI0921593A2 (pt) 2015-08-18
US20140323735A1 (en) 2014-10-30
CL2011001093A1 (es) 2011-09-02
US11723900B2 (en) 2023-08-15
US10722504B2 (en) 2020-07-28
US10576073B2 (en) 2020-03-03
RU2503662C2 (ru) 2014-01-10
US20200000792A1 (en) 2020-01-02
US20140045892A1 (en) 2014-02-13
EP2358675B9 (en) 2019-09-11
US20130030185A1 (en) 2013-01-31
US20120277438A1 (en) 2012-11-01
CA2742114C (en) 2016-09-13
US20100125093A1 (en) 2010-05-20
US20140057944A1 (en) 2014-02-27
KR20110082197A (ko) 2011-07-18
EP2358674B1 (en) 2013-01-02
US8247433B2 (en) 2012-08-21
EP2358674A1 (en) 2011-08-24
HRP20120920T1 (hr) 2013-01-31
US20210290608A1 (en) 2021-09-23
KR20110082085A (ko) 2011-07-15
DK2358675T3 (da) 2013-01-14
US9187423B2 (en) 2015-11-17
BRPI0921593B8 (pt) 2021-05-25
EP2358676B1 (en) 2012-10-10
MX2011005088A (es) 2011-06-01
BRPI0921596B1 (pt) 2021-10-26
SI2358676T1 (sl) 2013-01-31
IL212230A (en) 2014-12-31
US20100125141A1 (en) 2010-05-20
HRP20120897T1 (hr) 2012-12-31
CA2742105A1 (en) 2010-05-20
RU2515612C2 (ru) 2014-05-20
US12239638B2 (en) 2025-03-04
KR101656339B1 (ko) 2016-09-09
TWI461407B (zh) 2014-11-21
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
US20180289687A1 (en) 2018-10-11
ES2401224T3 (es) 2013-04-17
MX2011005089A (es) 2011-07-29
RU2011123890A (ru) 2012-12-20
TW201024263A (en) 2010-07-01
US11596624B2 (en) 2023-03-07
SMT201300033B (it) 2013-05-06
TW201024264A (en) 2010-07-01
PL2358674T3 (pl) 2013-06-28
EP2358675B1 (en) 2012-10-03
CA2742114A1 (en) 2010-05-20
CA2742105C (en) 2016-09-13
IL212452A0 (en) 2011-06-30
CN102209712A (zh) 2011-10-05
HK1160449A1 (en) 2012-08-17
DK2358674T3 (da) 2013-04-08
ES2396583T3 (es) 2013-02-22
SMT201200065B (it) 2013-03-08
US8304433B2 (en) 2012-11-06
US9162982B2 (en) 2015-10-20
PT2358676E (pt) 2012-12-06
CO6361993A2 (es) 2012-01-20
TWI441810B (zh) 2014-06-21
EP2358675A1 (en) 2011-08-24
BRPI0921595B1 (pt) 2020-10-13
MX2011005090A (es) 2011-09-06
SG171311A1 (en) 2011-07-28
AR074350A1 (es) 2011-01-12
AR074128A1 (es) 2010-12-22
AU2009313948A1 (en) 2010-05-20
SI2358675T1 (sl) 2013-01-31
AU2009313951B2 (en) 2015-03-12
CA2739992C (en) 2016-09-20
NZ592543A (en) 2013-02-22
JP5529150B2 (ja) 2014-06-25
ZA201103495B (en) 2012-01-25
RU2011123875A (ru) 2012-12-20
US20240316024A1 (en) 2024-09-26
ES2397247T3 (es) 2013-03-05
US20180055830A1 (en) 2018-03-01
PL2358676T3 (pl) 2013-03-29
JP2012508760A (ja) 2012-04-12
EP2358676A1 (en) 2011-08-24
JP2014098033A (ja) 2014-05-29
US10206913B2 (en) 2019-02-19
JP2014139209A (ja) 2014-07-31
TWI443087B (zh) 2014-07-01
AU2009313949B2 (en) 2015-03-19
JP5598798B2 (ja) 2014-10-01
US20160022660A1 (en) 2016-01-28
US20160184288A1 (en) 2016-06-30
WO2010056941A1 (en) 2010-05-20
US20200316047A1 (en) 2020-10-08
DK2358676T3 (da) 2013-01-14
KR20110082196A (ko) 2011-07-18
JP2012508761A (ja) 2012-04-12
KR101656338B1 (ko) 2016-09-09
JP5506813B2 (ja) 2014-05-28
KR101685186B1 (ko) 2016-12-09
US10946006B2 (en) 2021-03-16
US20220087995A1 (en) 2022-03-24
WO2010056938A1 (en) 2010-05-20
CY1113622T1 (el) 2016-06-22
CN102209712B (zh) 2016-04-06
MY151211A (en) 2014-04-30
US10034870B2 (en) 2018-07-31

Similar Documents

Publication Publication Date Title
NO2017036I1 (no) Daklatasvir og farmasøytisk akseptable salter derav, spesielt daklatasvir dihydroklorid
EP2085383A4 (en) Piperidin derivatives or salts thereof
ZA201103495B (en) 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compounds
IL189781A0 (en) Sulphonylpyrrole hydrochloride salts and pharmaceutical compositions containing the same
ITFI20080097A1 (it) "una testina tosaerba a filo utilizzabile alternativamente su macchine a rotazione destra o sinistra"
IL261853A (en) 6-[(4-fluorophenyl)methyl]-4-(3-nitrophenyl)-1,3-benzothiazole-2-amine and its salts
PL2049111T3 (pl) Pochodne 1-(acetylo)-piperydyny oraz 1-(acetylo)-piperazyny jako środki grzybobójcze do stosowania w ochronie roślin
ITVI20050152A1 (it) Cartuccia per la conservazione e l'erogazione sterile di un composto bifasico, particolarmente per una resina acrilica
BRPI0923380A2 (pt) Processos para a preparação de compostos de piperazina e sais de hidrocloreto dos mesmos
MX2010003989A (es) Composicion zibotentan que contiene mannitol y/o celulosa microcristalina.
BR112013002651A2 (pt) forma sólida do sal de cloridrato de 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oxi]etil]morfolina, processo para o preparo da mesma, uso mesma e composição farmacêutica compreendendo a mesma
EP2379174A4 (en) PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
SM200500011A (it) Una composizione farmaceutica antimicobatterica
FR2938428B1 (fr) Lit a barriere laterale composee de plusieurs barres s'etendant horizontalement
AR067168A1 (es) Forma polimorfica cristalina de -7 - etil-10 hidroxicamptotecina
HUE037259T2 (hu) N-alfa(2,4,6-triizopropil-fenil-szulfonil)-3-hidroxi-amidino-(L)-fenilalanin-4-etoxi-karbonilpiperazid és/vagy sóinak kristályos módosulatai
TNSN08461A1 (en) Crystalline forms of 4-[2-(4-methylphenylsulfanyl)-phenyl]piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain.
ITBO20040583A1 (it) Procedimento di rilievo e gestione di guasti particolarmente per macchine industriali
EP1892241A4 (en) NEW PIPERIDINE DERIVATIVE
CL2007003136A1 (es) Composicion farmaceutica analgesica que comprende una combinacion de carisoprodol, sus enantiomeros o sus sales cristalinas y clonixinato de lisina o sus hidratos o sus sales, en una proporcion carisoprodol:clonixinato de lisina desde 1:0,5 hasta 1:1
UA95801C2 (ru) Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
FR2894810B1 (fr) Compositions cosmetiques destinees a ameliorer la protection cellulaire vis-a-vis des uva
BRPI0912342A2 (pt) tiazolidinonas, oxazolidinonas substituídas terapêuticas, e compostos relacionados
PE20060480A1 (es) Sal cristalina de d-tartrato de 1-(indol-6-carbonil-d-fenilglicinil)-4-(1-metilpiperidin-4-il)piperazina

Legal Events

Date Code Title Description
FB Suspension of granting procedure